Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.
As of the June 30, 2025, cutoff date, daraxonrasib monotherapy data from long-term follow-up in second-line (2L) metastatic pancreatic ductal adenocarcinoma (PDAC) showed antitumor activity and durability, with the following results for patients with second-line (2L) RAS mutant PDAC with a RAS G12X mutation (n=26) or any RAS mutation (n=38), respectively:
